Keybanc analyst Scott Schoenhaus downgrades Benefitfocus (NASDAQ:BNFT) from Overweight to Sector Weight.
HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $54
HC Wainwright & Co. analyst Ed Arce maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and raises the price target from $53 to $54.